Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | HTR3A | P46098 | 1/20 | 0.44 |
| ▸ | HTR6 | P50406 | 1/20 | 0.44 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16815245 | 0.87 | SORD (0.42) | CHRM4CHRM5CHRM1CHRM3HTR2A | |
| SCHEMBL2316464 | 0.87 | LOXL2 (0.42) | CHRM4CHRM5CHRM1CHRM3HTR2A | |
| SCHEMBL19630564 | 0.84 | SMN1; SMN2 (0.44) | L3MBTL1MEN1KMT2AALDH1A1BRD4 | |
| SCHEMBL11629563 | 0.83 | MEN1 (0.42) | CHRM4CHRM5CHRM1CHRM3HTR2A | |
| SCHEMBL23931342 | 0.81 | HTR2C (0.47) | HTR2CL3MBTL1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL11632336 | 0.80 | ALDH1A1 (0.39) | L3MBTL1MEN1KMT2AALDH1A1BRD4 | |
| SCHEMBL9391551 | 0.78 | ALDH1A1 (0.43) | CHRM4CHRM5CHRM1CHRM3HTR2A | |
| SCHEMBL265376 | 0.78 | ALDH1A1 (0.47) | CALM1L3MBTL1ALDH1A1BRD4TAAR1 | |
| SCHEMBL2245915 | 0.78 | BRD4 (0.42) | CALM1L3MBTL1ALDH1A1BRD4TAAR1 | |
| SCHEMBL19591020 | 0.78 | GRM4 (0.43) | CALM1L3MBTL1ALDH1A1BRD4TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394955-B2 | 2,4 (4,6) pyrimidine derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-03-12 | — | — | US | disclosed |
| US-8148388-B2 | 2,4 (4,6) pyrimidine derivatives | JANSSEN PHARMACEUTICA, N.V. (BE) | 2012-04-03 | — | — | US | disclosed |
| US-20120065395-A1 | 2,4 (4,6) PYRIMIDINE DERIVATIVES | FREYNE EDDY JEAN EDGARD (BE) | 2012-03-15 | — | — | US | disclosed |
| US-20100160310-A1 | 2,4 (4,6) PYRIMIDINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-06-24 | — | — | US | disclosed |
| CN-101468965-A | Biaryl substituted 6-membered heterocyles as sodium channel blockers | MERCK & CO INC (US) | 2009-07-01 | — | — | CN | disclosed |
| CN-1791580-A | Biaryl substituted 6-membered heterocyclic sodium channel blockers | MERCK & CO INC (US) | 2006-06-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065395-A1 | 2,4 (4,6) PYRIMIDINE DERIVATIVES | NR0B1, NR1H3, NCOA3 | CHRM4 297/4885CHRM5 286/4885CHRM1 193/4885 |
| US-20100160310-A1 | 2,4 (4,6) PYRIMIDINE DERIVATIVES | NR1H3, NR1H2, NR0B1 | CHRM4 316/4885CHRM5 290/4885CHRM1 197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.